flu360 WE'VE GOT FLU COVERED®

2026-2027 Flu Season:
CSL Seqirus Pre-Book Offer

Federation of Pharmacy Networks

THE BENEFITS OF PARTNERING WITH CSL SEQIRUS FOR YOUR FLU SEASON PRE-BOOK INCLUDE*:

FIRM DOSE DISCOUNT

3 % discount on orders placed by April 17, 2026

PROMPT PAY DISCOUNT

2 % discount on orders placed directly from CSL Seqirus and paid in full within 60 days

RISK SHARING

15 % return of each product ordered and unused by the end of the season

FLU VACCINE DELIVERY EXPECTATIONS:	8/28/2026	9/25/2026	10/09/2026
	35%	75%	100%

	FLUAD influenza vaccine, adjuvanted	FLUCELVAX Influenza Vaccine
	65+ years	6+ months
	0.5-mL Pre-filled Syringe	0.5-mL Pre-filled Syringe
NET PRICE/UNIT†	$537.37	$280.88

ORDERING: Order direct at flu360.com or through your authorized wholesale distributor FFF Enterprises.

When it comes to pre-booking, we make it easy—because **we've got flu covered®**.

Visit **flu360.com** to place your pre-book reservation, manage your account, and access vaccination resources as part of your partnership with CSL Seqirus.

*Terms and conditions apply. Visit flu360.com for additional details.

†Inclusive of firm dose discount. Does not include federal excise tax. Additional discounts may apply inclusive of agreement discounts. Price/Unit is 10 doses, or 1 box of product.

CSL Seqirus

FLUAD® (Influenza Vaccine, Adjuvanted) and FLUCELVAX® (Influenza Vaccine) INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

FLUAD is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in adults 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

FLUCELVAX is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUCELVAX is approved for use in persons 6 months of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer FLUAD to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.

Do not administer FLUCELVAX to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of receipt of previous influenza vaccine, the decision to give FLUAD or FLUCELVAX should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUAD or FLUCELVAX.

Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.

The immune response to FLUAD and FLUCELVAX in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Vaccination with FLUAD or FLUCELVAX may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

FLUAD:
The most common (≥10%) local and systemic adverse reactions in adults 65 years of age and older who received FLUAD were injection site pain (25%), injection site tenderness (21%), myalgia (15%), fatigue (13%) and headache (13%). Other adverse events may occur.

FLUCELVAX:
Data for FLUCELVAX QUADRIVALENT are relevant to FLUCELVAX because both vaccines are manufactured using the same process and have overlapping compositions.

In children 6 months through 3 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (28%), erythema (26%), induration (17%) and ecchymosis (11%). The most common systemic adverse reactions were irritability (28%), sleepiness (27%), diarrhea (18%) and change of eating habits (17%).

In children 4 through 8 years of age who received FLUCELVAX, the most commonly reported local injection-site adverse reactions were pain (29%) and erythema (11%). The most common systemic adverse reaction was fatigue (10%).

In children and adolescents 9 through 17 years of age who received FLUCELVAX, the most commonly reported injection-site adverse reactions were pain (34%) and erythema (14%). The most common systemic adverse reactions were myalgia (15%) and headache (14%).

In adults 18 through 64 years of age who received FLUCELVAX, the most commonly reported injection-site adverse reactions were pain (28%) and erythema (13%). The most common systemic adverse reactions were headache (16%), fatigue (12%), myalgia (11%) and malaise (10%).

In adults ≥65 years who received FLUCELVAX the most commonly reported injection-site reaction was erythema (10%). The most common systemic adverse reactions were fatigue (11%), headache (10%) and malaise (10%).

Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Before administration, please see the full US Prescribing Information for FLUAD and FLUCELVAX.

Visit www.flu360.com for the full US Prescribing Information for FLUAD and FLUCELVAX

For US Healthcare Professionals Only

Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA

CSL Seqirus